Overview

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

Status:
Terminated
Trial end date:
2021-06-03
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Heron Therapeutics
Treatments:
Aprepitant